MEI Pharma cut to Hold at Truist after decision to discontinue zandelisib

Truist analyst Robyn Karnauskas downgraded MEI Pharma to Hold from Buy. The analyst cites the company’s decision to discontinue the development of its lead drug Zandelisib based on the feedback from the FDA meeting, along with its announcement of a 30% workforce reduction.